2. Cell Cycle/DNA Damage Protein Tyrosine Kinase/RTK JAK/STAT Signaling Epigenetics Stem Cell/Wnt
  3. Polo-like Kinase (PLK) Btk JAK
  4. LFM-A13

LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research

For research use only. We do not sell to patients.

LFM-A13 Chemical Structure

LFM-A13 Chemical Structure

CAS No. : 62004-35-7

Size Price Stock Quantity
5 mg USD 95 In-stock
10 mg USD 155 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of LFM-A13:

LFM-A13 Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE LFM-A13

View All Polo-like Kinase (PLK) Isoform Specific Products:

View All Isoforms
PLK1 PLK2 PLK3 PLK4

View All JAK Isoform Specific Products:

View All Isoforms
JAK1 JAK2 JAK3 Tyk2 JAK

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research[1][3][4]

IC50 & Target[1][3]

Plx1

10 μM (IC50)

PLK3

61 μM (IC50)

BRK

267 μM (IC50)

BMX

281 μM (IC50)

FYN

240 μM (IC50)

Met

215 μM (IC50)

Btk

2.5 μM (IC50)

In Vitro

LFM-A13 (100 μM; 4 h) inhibits Epo-induced phosphorylation of EpoR, JAK2, BTK, STAT5, and ERK1/2 in R10 cells[2].
LFM-A13 (100 μM; transfection 48 h) inhibits the autophosphorylation of JAK2, Tec and BTK in COS cells without affecting the autophosphorylation of Lyn kinase[2].
LFM-A13 potently inhibits Plx1 with IC50 of 10 μM; also inhibits BRK, BMX, FYN and Met with IC50s of 267, 281, 240 and 215 μM, respectively[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

LFM-A13 Related Antibodies

Cell Proliferation Assay[3]

Cell Line: PTK1 cells
Concentration: 100 µM
Incubation Time: 2 h
Result: Significantly arrested cycle progression.
In Vivo

LFM-A13 (10 or 50 mg/kg; i.p.) exhibits anti-tumor effects dose dependently in the MMTV/Neu transgenic mouse model of breast cancer[3]. FM-A13 (50 mg/kg; tiw; i.p.) attenuates DMBA-induced mammary tumorigenesis in mice by modulating a variety of factors associated with cell cycle, survival and apoptosis[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MMTV/neu transgenic mouse model[3]
Dosage: 50 or 100 mg/kg
Administration: Intraperitoneal injection (i.p.); twice a day for 5 consecutive days a week
Result: Attenuated mammary tumor formation in mice.
Animal Model: DMBA-induced breast cancer mouse model[4]
Dosage: 50 mg/kg (or combinated with Paclitaxel (HY-B0015) (10 mg/kg; once per week intraperitoneally))
Administration: Intraperitoneal injection (i.p.); 3 times a week
Result: Inhibited DMBA-induced mammary tumor incidence, average tumor number, average tumor weight, and size in BALB/c mice.
Significantly decreased PLK1, cyclin D1, CDK-4, P53 and Bcl-2 expression, but increased the expression of p21, IκB, Bax and caspase 3 expression in mice.
Molecular Weight

360.00

Formula

C11H8Br2N2O2
CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

C/C(O)=C(C#N)/C(NC1=CC(Br)=CC=C1Br)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 250 mg/mL (694.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7778 mL 13.8889 mL 27.7778 mL
5 mM 0.5556 mL 2.7778 mL 5.5556 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

The following protocol is derived from the literature and is for reference only. It is recommended to first try a small sample.

  • Protocol 1

    LFM-A13 was dissolved in a solution containing 10% DMS0[3]

  • Protocol 2

    LFM-A13 was dissolved in a solution containing 15% DMS0[4]

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.7778 mL 13.8889 mL 27.7778 mL 69.4444 mL
5 mM 0.5556 mL 2.7778 mL 5.5556 mL 13.8889 mL
10 mM 0.2778 mL 1.3889 mL 2.7778 mL 6.9444 mL
15 mM 0.1852 mL 0.9259 mL 1.8519 mL 4.6296 mL
20 mM 0.1389 mL 0.6944 mL 1.3889 mL 3.4722 mL
25 mM 0.1111 mL 0.5556 mL 1.1111 mL 2.7778 mL
30 mM 0.0926 mL 0.4630 mL 0.9259 mL 2.3148 mL
40 mM 0.0694 mL 0.3472 mL 0.6944 mL 1.7361 mL
50 mM 0.0556 mL 0.2778 mL 0.5556 mL 1.3889 mL
60 mM 0.0463 mL 0.2315 mL 0.4630 mL 1.1574 mL
80 mM 0.0347 mL 0.1736 mL 0.3472 mL 0.8681 mL
100 mM 0.0278 mL 0.1389 mL 0.2778 mL 0.6944 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

LFM-A13 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

LFM-A1362004-35-7Polo-like Kinase (PLK)BtkJAKBruton tyrosine kinaseJanus kinaseancertransgenic mouseDMBAcytokine signallingBreast cancercarcinogenicInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
LFM-A13
Cat. No.:
HY-110002
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.